Published within
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.
Published By Datamonitor
|
29 Jun 2010 |
|
Expert View
|
New data presented at the World Vaccines Congress demonstrate that BiondVax's developmental influenza vaccine can also act as a booster to existing seasonal influenza vaccines in elderly patients. A vaccine with increased efficacy in the elderly is one of the largest unmet needs in influenza prevention, although the need for patients to take multiple vaccinations may hinder its success.
Published By Datamonitor
|
13 Apr 2012 |
|
CommentWire
|
Emergent Biosolutions' agreement to buy the influenza vaccine FluBlok indicates a continued interest in expanding its infectious diseases portfolio, following acquisitions related to anthrax vaccination. This latest addition, once approved, will enable entry into the expanding influenza sector, which is predicted to reach total sales of almost $5 billion by 2016 across the seven major markets.
Published By Datamonitor
|
29 May 2008 |
|
CommentWire
|
Following poor uptake of the vaccine in several European markets, the UK Department of Health has opted to limit its H1N1 contract with GlaxoSmithKline to 34.8 million doses. Despite the media hype surrounding the influenza outbreak, the mild course of the pandemic and negative public opinion of the vaccine means that its commercial impact will be significantly reduced.
Published By Datamonitor
|
08 Apr 2010 |
|
Expert View
|
Johnson & Johnson and Crucell have entered into an agreement to develop and commercialize Crucell's universal influenza antibodies for the treatment and prevention of influenza. The deal strengthens Johnson & Johnson's presence in infectious diseases and gives it its first foothold in vaccines. Moreover, the deal is indicative of healthcare firms' increasing interest in influenza vaccines.
Published By Datamonitor
|
01 Oct 2009 |
|
CommentWire
|
US biotech Novavax has initiated a pivotal two-stage study for its H1N1 influenza vaccine in Mexico. Novavax's strategy of pursuing approval for the vaccine in smaller markets before targeting the US represents an alternative and faster route to market. Given the many benefits of this strategy, Datamonitor believes that it may be adopted by other small vaccine companies in the future.
Published By Datamonitor
|
21 Oct 2009 |
|
Expert View
|
The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.
Published By Datamonitor
|
08 May 2009 |
|
CommentWire
|
Sales of Tamiflu, Roche's influenza treatment, have plummeted by 68% compared to 2007, reflecting the waning attention paid to pandemic preparation by governments worldwide and the emerging competition from Relenza and pandemic influenza vaccines. Despite insufficient stockpiles in most countries, Datamonitor believes that the seasonal market will continue to gain importance for Tamiflu's sales.
Published By Datamonitor
|
05 Feb 2009 |
|
Expert View
|
The need for yearly updates and the low coverage of existing influenza vaccines has created an unmet need for products providing a wider and longer-lasting immunity. Several companies are therefore developing "universal" influenza vaccines that make annual vaccination unnecessary, mainly targeting the highly conserved M2e domain of the virus, although doubts regarding their real benefits remain.
Published By Datamonitor
|
23 Nov 2007 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.